4,294 Shares in Illumina, Inc. $ILMN Purchased by Optimize Financial Inc

Optimize Financial Inc purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,294 shares of the life sciences company’s stock, valued at approximately $408,000.

Other large investors have also recently made changes to their positions in the company. Next Capital Management LLC purchased a new position in Illumina during the 2nd quarter valued at about $341,000. CWM LLC increased its position in Illumina by 112.9% during the 2nd quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock valued at $7,319,000 after buying an additional 40,676 shares in the last quarter. Generali Asset Management SPA SGR increased its position in Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock valued at $2,113,000 after buying an additional 7,574 shares in the last quarter. Andra AP fonden raised its stake in Illumina by 426.3% during the second quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after buying an additional 83,017 shares during the last quarter. Finally, Aaron Wealth Advisors LLC boosted its holdings in Illumina by 342.6% in the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock worth $995,000 after acquiring an additional 8,109 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Evercore ISI reiterated an “outperform” rating and issued a $155.00 price target on shares of Illumina in a research note on Monday, January 5th. Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Finally, Barclays boosted their price target on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $127.18.

Illumina Stock Performance

NASDAQ:ILMN opened at $134.19 on Thursday. The stock has a 50-day simple moving average of $138.59 and a two-hundred day simple moving average of $115.87. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The firm has a market capitalization of $20.50 billion, a PE ratio of 30.09, a P/E/G ratio of 2.25 and a beta of 1.45.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.